Status:
ACTIVE_NOT_RECRUITING
The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors
Lead Sponsor:
Chulalongkorn University
Conditions:
Empagliflozin in Post AKI Stage 2-3
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Effects of Empagliflozin compared with placebo in post severe acute kidney injury survivors, evaluated by MAKE365.
Eligibility Criteria
Inclusion
- post AKI stage 2-3
- CrCl \> 20
Exclusion
- pregnancy
- post kidney transplant
- previous use of SGLT2 Inhibitors
- history of ketoacidosis
Key Trial Info
Start Date :
July 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2026
Estimated Enrollment :
147 Patients enrolled
Trial Details
Trial ID
NCT05360615
Start Date
July 1 2022
End Date
July 1 2026
Last Update
August 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Central Chest Institute of Thailand
Nonthaburi, Mueang Nonthaburi District, Thailand, 11000